Search results for "AGENTS"

showing 10 items of 7330 documents

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mel…

2005

The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2.A total of 179 patients were recruited and randomly assigned to one treatment group. Metabolic control (HbA1c), insulin resistance (HOMA index), and microvascular function (laser Doppler fluxmetry) were observed at baseline and after 3 and 6 months.HbA1c improved in both treatment arms (pioglitazone: 7.52 +/- 0.85% to 6.71 +/- 0.89%, p.0001; glimepiride: 7.44 +/- 0.89% to 6.83 +/- 0.85%, p.0001). Insulin-resistance decreased significantly in the pioglitazone group (6.15 +/- 4.05 to 3.85 +/- 1.92, p…

AdultBlood GlucoseMalemedicine.medical_specialtyEndotheliumPhysiologyArbitrary unitInsulin resistancePhysiology (medical)Diabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsMolecular BiologyAgedPioglitazonebusiness.industryMicrocirculationGlucose clamp techniqueMiddle Agedmedicine.diseaseGlimepirideEndocrinologymedicine.anatomical_structureSulfonylurea CompoundsDiabetes Mellitus Type 2Metabolic control analysisGlucose Clamp TechniqueFemaleThiazolidinedionesEndothelium VascularInsulin ResistanceCardiology and Cardiovascular MedicinebusinessPioglitazoneBlood Flow Velocitymedicine.drugMicrocirculation (New York, N.Y. : 1994)
researchProduct

Evaluation of CGMS® During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes

2006

CGMS (Medtronic Minimed, Duesseldorf, Germany) allows continuous glucose monitoring. Recent studies with invasive monitoring techniques revealed discrepancies in blood glucose measurements obtained from different anatomical sites compared with those from the fingertip. The aim of this study was to investigate the CGMS and a device for alternative site testing (AST) during dynamic blood glucose changes and to compare these results with fingertip measurements.Twelve patients with type 1 diabetes (seven women, five men; age, 33.3 +/- 8.7 years) received a 75-g oral glucose load. Insulin was applied intravenously (rapid glucose decline) or subcutaneously (moderate glucose decline) in a dosage b…

AdultBlood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyForearmDiabetes mellitusmedicineHumansHypoglycemic AgentsInsulinIn patientBlood Glucose MeasurementType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringSite testingInsulinGlucose MeasurementMiddle Agedmedicine.diseaseSurgeryMedical Laboratory TechnologyDiabetes Mellitus Type 1medicine.anatomical_structureAnesthesiaInjections IntravenousFemalebusinessDiabetes Technology & Therapeutics
researchProduct

Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1.

2010

Metabolic factors have been associated with liver damage in patients with genotype 1 chronic hepatitis C (G1 CHC). We tested visceral adiposity index (VAI), a new marker of adipose dysfunction in G1 CHC, patients to assess its association with host and viral factors and its link to both histological findings and sustained virological response (SVR). Two hundred thirtysix consecutive G1 CHC patients were evaluated by way of liver biopsy and anthropometric and metabolic measurements, including insulin resistance (IR), homeostasis model assessment (HOMA), and VAI using waist circumference, body mass index, triglycerides, and highdensity lipoprotein cholesterol. All biopsies were scored by one …

AdultBlood GlucoseMalemedicine.medical_specialtyPathologyAlcohol DrinkingGenotypeInterferon alpha-2Intra-Abdominal FatGastroenterologyAntiviral AgentsBody Mass IndexPolyethylene GlycolsInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansHepatologymedicine.diagnostic_testbusiness.industryCholesterol HDLInterferon-alphaAlanine TransaminaseHepatitis CHepatologyHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseRecombinant ProteinsFatty LiverDiabetes Mellitus Type 2Liver biopsyHypertensionRNA ViralFemaleSteatosisWaist CircumferencebusinessViral loadBody mass indexHepatology (Baltimore, Md.)
researchProduct

Resting Energy expenditure in type 2 diabetic patients and the effect of insulin bolus

2014

Aims: Resting energy expenditure (REE) plays a critical role in the regulation of body weight, with important implications in type 2 diabetes (T2D). However, the relationships between REE and T2D have not been extensively evaluated. We compared REE in persons with diabetes and in persons without diabetes. We also investigated the acute effect of insulin on REE and venous lactate, the latter an indirect measure of neoglucogenetic activity. Methods: REE was measured using indirect calorimetry in 14 newly diagnosed, untreated T2D adults and in 14 non-diabetic age-, gender- and body mass index-matched persons. The REE and lactate venous concentrations were also measured in a subgroup of 5 T2D p…

AdultBlood GlucoseMalemedicine.medical_specialtyRestEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesBody weightBody Mass IndexSettore MED/13 - EndocrinologiaEndocrinologyBolus (medicine)Internal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinResting energy expenditureSettore MED/49 - Scienze Tecniche Dietetiche ApplicateAgedbusiness.industryInsulinBody WeightCalorimetry IndirectGeneral MedicinePlasma glucose concentrationMiddle Agedmedicine.diseasediabetes insulin lactate neoglucogenesis resting energy expenditure indirect calorimetryEndocrinologyDiabetes Mellitus Type 2GluconeogenesisFemaleEnergy IntakeEnergy MetabolismbusinessFollow-Up Studies
researchProduct

Polymorphisms of the angiotensinogen gene and the outcome of microalbuminuria in essential hypertension: a 3-year follow-up study.

2003

Background: The objective of this study was to analyse the relationship of polymorphisms of the angiotensinogen (AGT) gene with the changes in microalbuminuria during 3 years of antihypertensive treatment in a group of young adults with essential hypertension. Methods: Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs and in the absence of diabetes mellitus were included. After the initial evaluation, patients were treated using only nonpharmacological measures (n=23), only β-blockers (n=26), only angiotensin-converting enzyme inhibitors (ACEi) (n=57) or a combination of treatments (n=25). The office blood pressure, biochemical profile and…

AdultBlood GlucoseMalemedicine.medical_specialtyTime FactorsGenotypeAdrenergic beta-AntagonistsAngiotensinogenAngiotensin-Converting Enzyme InhibitorsBlood PressureEssential hypertensionExcretionDiabetes mellitusInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive AgentsProteinuriaPolymorphism Geneticbusiness.industrymedicine.diseaseEndocrinologyBlood pressureTreatment OutcomeACE inhibitorHypertensionMicroalbuminuriaFemaleGene polymorphismmedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension

2005

The objective was to assess the temporal impact of factors related to the development of microalbuminuria during the follow-up of young adult normoalbuminurics with high-normal blood pressure or at stage 1 of essential hypertension. Prospective follow-up was conducted on 245 normoalbuminuric hypertensive subjects (mean age 40.9 years; 134 men; blood pressure 139.7/88.6 mm Hg; body mass index 28.5 kg/m 2 ) never treated previously with antihypertensive drugs, with yearly urinary albumin excretion measurements, until the development of microalbuminuria. After enrollment, patients were placed on usual care including nonpharmacological treatment or with an antihypertensive drug regime to achie…

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classBlood PressureEssential hypertensionPrehypertensionRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansProspective StudiesAntihypertensive drugAntihypertensive AgentsProportional Hazards ModelsProteinuriabusiness.industryFastingmedicine.diseaseEndocrinologyBlood pressureHypertensionMultivariate AnalysisDisease ProgressionAlbuminuriaCardiologyFemaleMicroalbuminuriamedicine.symptombusinessBody mass indexFollow-Up StudiesHypertension
researchProduct

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.

2000

In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance. These patients had elevated PAI activity and antigen and t-PA antigen levels at rest and after venous occlusion. Gemfibrozil reduced plasma triglyceride levels (P0.001), whereas it increased free fatty acids (P0.05) and high density lipoprotein cholesterol levels (P0.05). In those patients reaching normalization of plasma triglyceride levels (triglyceride reductionor =50%) (n=15), insulin levels (P0.05) as well as the …

AdultBlood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentFatty Acids NonesterifiedPlaceboFibrinogenInsulin resistanceDouble-Blind MethodInternal medicinemedicineGemfibrozilHumansInsulinAgedHypolipidemic AgentsHypertriglyceridemiaHemostasisbusiness.industryT-plasminogen activatorInsulinHypertriglyceridemiaParallel studyGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyGemfibrozilInsulin ResistanceCardiology and Cardiovascular Medicinebusinessmedicine.drugAtherosclerosis
researchProduct

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

2008

BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Glargine is associated with reduced frequency of hypoglycemic episodes (mostly nocturnal) as well as effective glycemic control. Maintenance of good metabolic control before conception and throughout pregnancy is essential to lower the risk of fetal malformations. Glargine might be a valuable alternative in the management of pregnancies complicated by diabetes mellitus. However, because its clinical utility has not been established, the use of glargine is not currently recommended during pregnancy. OBJECTIVE: The aim of this study was to retrospectively evaluat…

AdultBlood Glucosemedicine.medical_specialtyInsulin IsophanePregnancy in DiabeticsInsulin GlargineSettore MED/13 - EndocrinologiaInsulin aspartPregnancyDiabetes mellitusInternal medicinemedicineOutpatient clinicInsulin lisproHumansHypoglycemic AgentsInsulinPharmacology (medical)Body Weights and MeasuresFemurInsulin AspartGlycemicRetrospective StudiesPharmacologyGlycated HemoglobinType 1 diabetesPregnancyInsulin LisproInsulin glarginebusiness.industryglargine type 1 diabetesPregnancy Outcomemedicine.diseaseInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Case-Control StudiesFemalebusinessmedicine.drugClinical therapeutics
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct